Email Alert RSS
Volume 12 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Abstract
References
Related Articles
TAN Yu-ting, SHI Xiao-chun, LIU Xiao-qing. Testing and Prophylaxis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 86-91. DOI: 10.12290/xhyxzz.20180406
Citation: TAN Yu-ting, SHI Xiao-chun, LIU Xiao-qing. Testing and Prophylaxis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonists[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(1): 86-91. DOI: 10.12290/xhyxzz.20180406
shu

Testing and Prophylaxis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonists

  • Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    LIU Xiao-qing Tel: 86-10-69155087, E-mail: liuxqpumch@126.com

  • Received Date: September 16, 2018
  • Accepted Date: May 12, 2019
  • Available Online: June 04, 2019
  • Issue Publish Date: January 29, 2021
    Graphical Abstract
    • Abstract
  • Treatment with tumor necrosis factor-α(TNF-α) antagonists is a risk factor for active tuberculosis. Especially for patients with latent tuberculosis infection (LTBI), the risk of tuberculosis reactivation is greater, which lays weight on the importance of the screening of LTBI and the choice of treatment regimens in this population. 2015 World Health Organization (WHO) guidelines on the management of LTBI strongly recommended that patients should receive LTBI screening before using TNF-α antagonists. Furthermore, there were five regimens recommended. However, no data are available on the efficacy and safety of the five regimens in this population in WHO guidelines. This review focuses on the screening and treatment of LTBI in patients receiving TNF-α antagonists, in order to provide a basis for the management of LTBI in clinical practice.
    • FullText(HTML)
    • References (44)
  • [1]
    WHO. WHO Global tuberculosis report 2019[R/L ].[2019-10-11]. http://www.who.int/tb/publications/global_ repo rt/zh/.
    [2]
    Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guide-lines for low tuberculosis burden countries[J]. Eur Respir J, 2015, 46: 1563-1576. DOI: 10.1183/13993003.01245-2015
    [3]
    Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement[J]. Eur Respir J, 2010, 36: 1185-1206. DOI: 10.1183/09031936.00028510
    [4]
    Ai JW, Ruan QL, Liu QH, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements[J]. Emerg Microbes Infect, 2016, 3: e10.
    [5]
    Goletti D, Petrone L, Ippolito G, et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs[J]. Expert Rev Anti Infect Ther, 2018, 16: 501-512. DOI: 10.1080/14787210.2018.1483238
    [6]
    Ernst JD. The immunological life cycle of tuberculosis[J]. Nat Rev Immunol, 2012, 12: 581-591. DOI: 10.1038/nri3259
    [7]
    Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry[J]. Arthritis Rheum, 2009, 60: 1884-1894. DOI: 10.1002/art.24632
    [8]
    Liao H, Zhong Z, Liu Z, et al. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis[J]. Int J Rheum Dis, 2017, 20: 161-168. DOI: 10.1111/1756-185X.12970
    [9]
    Ai JW, Zhang S, Ruan QL, et al.The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-alpha Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies[J]. J Rheumatol, 2015, 42: 2229-2237. DOI: 10.3899/jrheum.150057
    [10]
    Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis[J]. Ann Rheum Dis, 2015, 74: 538-546. DOI: 10.1136/annrheumdis-2013-204195
    [11]
    Zhou Q, Zhou Y, Chen H, et al. The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials[J]. Int J Clin Exp Med, 2014, 7: 3870-3880.
    [12]
    Iannone F, Cantini F, Lapadula G. Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: international recommendations[J]. J Rheumatol Suppl, 2014, 91: 41-46. DOI: 10.3899/jrheum.140101
    [13]
    肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组.肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识[J].中华风湿病学杂志, 2013, 17: 508-512. DOI: 10.3760/cma.j.issn.1007-7480.2013.08.002
    [14]
    Wong SH, Gao Q, Tsoi KK, et al. Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis[J]. Thorax, 2016, 71: 64-72. DOI: 10.1136/thoraxjnl-2015-207811
    [15]
    Vassilopoulos D, Tsikrika S, Hatzara C, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy[J]. Clin Vaccine Immunol, 2011, 18: 2102-2108. DOI: 10.1128/CVI.05299-11
    [16]
    Wong SH, Ip M, Tang W, et al. Performance of interferon-gamma release assay for tuberculosis screening in inflamma-tory bowel disease patients[J]. Inflamm Bowel Dis, 2014, 20: 2067-2072. DOI: 10.1097/MIB.0000000000000147
    [17]
    边赛男, 刘晓清.γ-干扰素释放试验在免疫功能抑制人群中诊断结核分枝杆菌感染的应用[J].中华实验和临床感染病杂志(电子版), 2017, 11: 117-120. DOI: 10.3877/cma.j.issn.1674-1358.2017.02.003
    [18]
    Kisacik B, Pamuk ON, Onat AM, et al. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-alpha Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence[J]. J Rheumatol, 2016, 43: 524-529. DOI: 10.3899/jrheum.150177
    [19]
    Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers[J]. Ann Rheum Dis, 2003, 62: 791. DOI: 10.1136/ard.62.8.791
    [20]
    British Thoracic Society Standards of Care Committee.BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment[J]. Thorax, 2005, 60: 800-805. DOI: 10.1136/thx.2005.046797
    [21]
    Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists[J]. Arthritis Rheum, 2005, 52: 1766-1772. DOI: 10.1002/art.21043
    [22]
    Koike R, Takeuchi T, Eguchi K, et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis[J]. Mod Rheumatol, 2007, 17: 451-458. DOI: 10.3109/s10165-007-0626-3
    [23]
    Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy[J]. Swiss Med Wkly, 2007, 137: 620-622.
    [24]
    Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement[J]. Eur Respir J, 2010, 36: 1185-1206. DOI: 10.1183/09031936.00028510
    [25]
    Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis[J]. Arthritis Care Res (Hoboken), 2012, 64: 625-639. DOI: 10.1002/acr.21641
    [26]
    Center for Disease Control and Prevention. Latent tuberculo-sis infection: A guide for primary health care providers[EB/OL ]. [2018-09-17]. http://www.cdc.gov/tb/publications/ltbi/treatment.htm#treatmentR egimens.
    [27]
    Favalli EG, Caporali R, Sinigaglia L, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology Ⅱ. Safety[J]. Clin Exp Rheumatol, 2011, 29: S15-S27.
    [28]
    Bombardier C, Hazlewood GS, Akhavan P, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part Ⅱ safety[J]. J Rheumatol, 2012, 39: 1583-1602. DOI: 10.3899/jrheum.120165
    [29]
    Gómez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection[J]. Arthritis Rheum, 2007, 57: 756-761. DOI: 10.1002/art.22768
    [30]
    Cagatay T, Aydin M, Sunmez S, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis[J]. Rheumatol Int, 2010, 30: 1459-1463. DOI: 10.1007/s00296-009-1170-6
    [31]
    Kisacik B, Pamuk ON, Onat AM, et al. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-alpha Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence[J]. J Rheumatol, 2016, 43: 524-529. DOI: 10.3899/jrheum.150177
    [32]
    Larppanichpoonphol P, Bagdure S, Amiri HM, et al. Poor compliance makes treatment of latent tuberculosis infection unsatisfactory[J]. J Prim Care Community Health, 2012, 3: 246-250. DOI: 10.1177/2150131912437936
    [33]
    Nobre CA, Callado MR, Lima JR, et al. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients[J]. Rheumatol Int, 2012, 32: 2769-2775. DOI: 10.1007/s00296-011-2017-5
    [34]
    Gomes CM, Terreri MT, Moraes-Pinto MI, et al. Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline-A longitudinal analysis after using TNFa blockers[J]. Mem Inst Oswaldo Cruz, 2015, 110: 921-928. DOI: 10.1590/0074-02760150235
    [35]
    Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection[J]. N Engl J Med, 2011, 365:2155-2166. DOI: 10.1056/NEJMoa1104875
    [36]
    Tomsic M, Rotar Z. The frequency of tuberculosis chemoprophylaxis prior to TNF-alpha inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registry[J]. Ann Rheum Dis, 2012, 71: 1909-1911. DOI: 10.1136/annrheumdis-2012-201913
    [37]
    Chang B, Park HY, Jeon K, et al. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea[J]. Clin Rheumatol, 2011, 30: 1535-1541. DOI: 10.1007/s10067-011-1771-9
    [38]
    Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculo-sis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test[J]. Br J Dermatol, 2009, 161: 797-800. DOI: 10.1111/j.1365-2133.2009.09331.x
    [39]
    Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020[J]. Am J Transplant, 2020, 20:1196-1206. DOI: 10.1111/ajt.15841
    [40]
    Lee EH, Kang YA, Leem AY, et al. Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection[J]. Sci Rep, 2017, 7: 6473. DOI: 10.1038/s41598-017-06899-1
    [41]
    Park SJ, Jo KW, Yoo B, et al. Comparison of LTBI treatment regimens for patients receiving anti-tumour necrosis factor therapy[J]. Int J Tuberc Lung Dis, 2015, 19: 342-348. DOI: 10.5588/ijtld.14.0554
    [42]
    Sung YK, Cho SK, Kim D, et al. Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy[J]. Korean J Intern Med, 2018, 33: 1016-1024. DOI: 10.3904/kjim.2016.214
    [43]
    Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin, rifabutin, and rifapentine drug interactions[J]. Curr Med Res Opin, 2013, 29:1-12.
    [44]
    Williamson B, Dooley KE, Zhang Y, et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine[J]. Antimicrob Agents Chemother, 2013, 57:6366-6369. DOI: 10.1128/AAC.01124-13
    • Related Articles

  • Related Articles

    [1]CHEN Weiyun, DAI Yi, QIAN Min, LIANG Jinqian. Perioperative Management of SEPN1-Related Myopathy Accompanying Scoliosis: A Case Report[J]. Medical Journal of Peking Union Medical College Hospital. DOI: 10.12290/xhyxzz.2024-0428
    [2]WANG Zhaojian, MA Xuda, XIE Jiangmiao, ZOU Kun, LONG Xiao. Protocol for the Development of Chinese Guideline for the Diagnosis and Management of Localized Scleroderma[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1311-1317. DOI: 10.12290/xhyxzz.2024-0656
    [3]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [4]LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281
    [5]National Center for Quality Assurance of Anesthesia. 2023 Chinese Expert Consensus Statement for Prevention and Management of Perioperative Hypothermia[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 734-743. DOI: 10.12290/xhyxzz.2023-0266
    [6]Joint Surgery Group of Beijing Medical Association Orthopaedic Branch. Expert Consensus on Community Management of Diagnosis and Treatment of Osteoarthritis and Osteoporosis in the Elderly (Version 2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 484-493. DOI: 10.12290/xhyxzz.2022-0699
    [7]ZUO Wei, LIU Rongji, SUN Yajia, ZHANG Bo, CHEN Yaolong, ZHANG Shuyang. Interpretation on Management Guideline for the Off-label Use of Drugs in China(2021 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 86-93. DOI: 10.12290/xhyxzz.2022-0588
    [8]ZUO Wei, LIU Rongji, NIU Ziran, DU Liping, CHANG Qing, PENG Hua, PAN Hui, ZHANG Bo. Establishment of the Management Systems for Off-label Drug Use in Medical Institution[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 1094-1099. DOI: 10.12290/xhyxzz.2022-0128
    [9]XU Shengyong, XU Jun, ZHU Huadong, YU Xuezhong. Strengthen the Management of Difficult Airway and Improve the Treatment of Clinical Practice: Interpretation on 2022 American Society of Anesthesiologists Practice Guidelines for Management of the Difficult Airway[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 427-432. DOI: 10.12290/xhyxzz.2022-0133
    [10]Miao MA, Rui-yi TANG, Rong CHEN. Management of Unscheduled Bleeding in Women Using Combined Oral Contraceptives[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 73-78. DOI: 10.3969/j.issn.1674-9081.20170182

  • Cited by

    Periodical cited type(28)

    1. 李妍，韩彤昕，毛华伟. 线上与线下医学人文教学结合应用的研究与探索. 中国继续医学教育. 2025(01): 185-188 .
    2. 李研，赵琳琳. 英美医学教育中戏剧元素的人文透视. 中国医学伦理学. 2025(03): 385-391 .
    3. 张慧颖，王锦帆，马宇昊，何源. 新时代中国医学人文研究热点及趋势探析. 中国医学伦理学. 2025(03): 336-345 .
    4. 王红宇，刘金强，丁俊杰，王红，孟志剑，唐聚花，张思森. 医患沟通技能培训在急重症医学住院医生规培中的应用. 中国现代医生. 2024(02): 74-76 .
    5. 向琳，王浩辰，黄天宇，何鲲. 基于“医教研德”复合型人才培养模式口腔种植学教学改革思考与探索. 中国医药导报. 2024(04): 70-73 .
    6. 俞婧，王瑞，武云. 基于VOSviewer的我国叙事医学相关文献的可视化分析及启示. 中国毕业后医学教育. 2024(03): 207-213 .
    7. 余航，安琪，金李，吴远，陈涛，肖懿慧. BOPPPS教学模式融合课程思政在本科生内科学见习中的应用. 医学教育研究与实践. 2024(03): 349-354 .
    8. 周殷华，程瑜，崔昌杰，田晓辉，符隆文，方婵，廖晓星，陈起坤. 医文融合视域下临床医学人文教学体系研究. 中国医学伦理学. 2024(07): 860-866 .
    9. 王京，贺欢欣，董智瑞，董健，赵明东. 住培医师人文素养的培育. 中国继续医学教育. 2024(20): 186-189 .
    10. 敖玲敏，沈菊. 中华优秀传统文化融入大学生心理健康教育的价值之维与实践之路. 黑龙江高教研究. 2024(12): 120-126 .
    11. 王倩，巩红，刘昌，李雁，李研，辛娟，张月浪. 以临床人文岗位胜任力为导向的医学人文多元教育渠道的探索. 医学教育研究与实践. 2023(01): 68-72 .
    12. 徐燕玲，顾漪. 临床医师医学人文认知现状调查. 中国现代医生. 2023(05): 135-138 .
    13. 冯悦，庞维，郑丽，李胜军，孙逊，冯辉. 新医科和新文科交叉融合对免疫学创新人才培养的探索性改革. 中国免疫学杂志. 2023(06): 1203-1206 .
    14. 柳舟，张亮，王璐，朱睿瑶，王慧娟，张静，雷佳羲，詹丽英. 重症医学科医学人文素质教育的改革与实践. 中国继续医学教育. 2023(12): 10-14 .
    15. 阳磊，彭蓓，张婉丽. 口腔科住院医师规范化培训医学人文教育改革实践. 经济研究导刊. 2023(12): 123-125 .
    16. 赵娟，徐斌. 进修医师自身免疫性肝炎临床带教体会. 继续医学教育. 2023(06): 129-132 .
    17. 刘琴，何自强，骆佳佳，冯凯娜. 以提升人文关怀能力为导向的护理学导论教学模式应用研究. 沈阳医学院学报. 2023(05): 540-543 .
    18. 谢佳君，何勇涛，黄国琼，秦宇彤，王方芳，栗昕，黄春基. 立德树人背景下医学生德育素质培养研究. 中国社会医学杂志. 2023(05): 540-543 .
    19. 吕晓龙，严旭，章涵. 以强化人文素养为导向的全科医学生叙事医学课程模式构建. 济源职业技术学院学报. 2023(04): 33-37 .
    20. 吕少春，宋汉君，栾海艳，何穆涵. 基于医学模拟教学的医学生临床能力培养研究. 医学教育研究与实践. 2022(03): 294-297 .
    21. 李超. 培养高素质临床医生路径分析. 继续医学教育. 2022(04): 61-64 .
    22. 冯矗，陈飞，张树霞，刘古月，李晓宇. 医学人文关怀教育融入外科实习的实践探索. 中医药管理杂志. 2022(11): 88-90 .
    23. 高铭，韩涛，池靖涵，杜振兰，杨常栓，侯豫，花少栋. 创新互动式医学人文教育在儿科住院医师规范化培训中的作用研究. 中国医学伦理学. 2022(07): 806-810 .
    24. 胡艳超，王洪涛，王怡雯，周戬平. 医学人文教育在心血管内科混合式教学中的应用. 医学教育研究与实践. 2022(05): 648-652 .
    25. 叶榆莹. 英语电影字幕翻译对医学生人文教育的作用探究. 才智. 2022(33): 62-65 .
    26. 陶庆才. 抗疫精神融入医学院校课程思政的研究与实践. 浙江医学教育. 2022(05): 268-270+299 .
    27. 张宏伟，熊梓彤，林芷伊. 英国医学人文关怀及其医学教育启示. 农垦医学. 2022(06): 561-564 .
    28. 祝贺，敖俊红，杨蓉娅，李海涛. 全媒体时代医学摄影的边界教育在皮肤病与性病科临床教学中的意义. 实用皮肤病学杂志. 2022(06): 367-369 .

    Other cited types(6)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (628) PDF downloads (51) Cited by(34)
    Related
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

      Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return
      x Close Forever Close